EQEquillium, Inc.

Nasdaq equilliumbio.com


$ 1.05 $ -0.41 (-27.89 %)    

Tuesday, 04-Jun-2024 15:59:41 EDT
QQQ $ 454.82 $ 1.24 (0.27 %)
DIA $ 398.57 $ 1.27 (0.33 %)
SPY $ 530.36 $ 0.59 (0.11 %)
TLT $ 91.26 $ 1.07 (1.17 %)
GLD $ 225.37 $ -1.95 (-0.9 %)
$ 1.06
$ 1.41
$ 0.00 x 0
$ 1.14 x 100
$ 1.01 - $ 1.43
$ 0.45 - $ 3.25
10,730,288
na
37.37M
$ 0.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-25-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-23-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-24-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 03-26-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-12-2019 06-30-2019 10-Q
21 05-13-2019 03-31-2019 10-Q
22 03-27-2019 12-31-2018 10-K
23 11-15-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nano-cap-equillium-shares-fall-after-patchy-hair-loss-study-data

Equillium released topline data from its Phase 2 study of EQ101 in adult patients with alopecia areata, a disease that results ...

 equillium-announces-topline-data-from-phase-2-study-of-eq101-in-alopecia-areata-20-of-all-subjects-that-completed-the-24-week-treatment-period-achieved-salt--20-eq101-was-well-tolerated-in-subjects-with-alopecia-areata-with-no-serious-adverse-events-reported

20% of all subjects that completed the 24-week treatment period achieved SALT ≤ 2029% of completed subjects with moderate to se...

 hc-wainwright--co-reiterates-buy-on-equillium-maintains-5-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $5 price target.

 hc-wainwright--co-maintains-buy-on-equillium-raises-price-target-to-5

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Equillium (NASDAQ:EQ) with a Buy and raises the price target fr...

 why-westport-fuel-systems-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected ...

 equillium-q4-earnings-insights
Equillium: Q4 Earnings Insights
03/25/2024 21:35:06

 equillium-q4-2023-gaap-eps-007-beats-017-estimate-sales-9200m-beat-6425m-estimate

Equillium (NASDAQ:EQ) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.17) by 58...

 cognizant-technology-solutions-to-rally-over-13-here-are-10-top-analyst-forecasts-for-tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION